No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AZN240712C79000
- 0.11
- +0.05+83.33%
15min DelayTrading Jul 10 12:58 ET
0.11High0.08Low
0.08Open0.06Pre Close17 Volume221 Open Interest79.00Strike Price153.00Turnover20.38%IV1.63%PremiumJul 12, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.11Extrinsic Value100Contract SizeAmericanOptions Type0.1892Delta0.2069Gamma556.04Leverage Ratio-0.0731Theta0.0010Rho105.21Eff Leverage0.0174Vega
Intraday
- 5D
- Daily
News
Deutsche Numis Reaffirms Their Hold Rating on AstraZeneca (AZN)
Express News | AstraZeneca : BMO Raises Target Price to $89 From $82
Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)
Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing
AstraZeneca PLC (AZN): Is This FTSE Dividend Stock a Good Buy Right Now?
AstraZeneca: Strong Sales Growth and Upward Guidance Potential Justify Buy Rating
Comments
1 PDUFA this week! 🔥
$Arcutis Biotherapeutics(ARQT.US$ : pending decision 🤔
⇨ ARQ-151 topical roflumilast cream
‣ Atopic Dermatitis (aged 6 & older children)
‣ PDUFA date: 7/7/24 (sNDA)
Upcoming PDUFAs & AdCom in July: 📅👇
$Phathom Pharmaceuticals(PHAT.US$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA date: 7/19/24 (NDA)
$AstraZeneca(AZN.US$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom date: 7/25/24(sBLA)
$BeiGene(BGNE.US$ :...
$Arcutis Biotherapeutics(ARQT.US$ : pending decision 🤔
⇨ ARQ-151 topical roflumilast cream
‣ Atopic Dermatitis (aged 6 & older children)
‣ PDUFA date: 7/7/24 (sNDA)
Upcoming PDUFAs & AdCom in July: 📅👇
$Phathom Pharmaceuticals(PHAT.US$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA date: 7/19/24 (NDA)
$AstraZeneca(AZN.US$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom date: 7/25/24(sBLA)
$BeiGene(BGNE.US$ :...
6
🔥 July: 3 PDUFAs & 1 AdCom
$Arcutis Biotherapeutics(ARQT.US$ : ARQ-151 topical roflumilast cream
$Phathom Pharmaceuticals(PHAT.US$ : VOQUEZNA® (vonoprazan)
$AstraZeneca(AZN.US$ : Imfinzi + chemotherapy - AdCom
$BeiGene(BGNE.US$ : TEVIMBRA (tislelizumab)
$Arcutis Biotherapeutics(ARQT.US$ : ARQ-151 topical roflumilast cream
$Phathom Pharmaceuticals(PHAT.US$ : VOQUEZNA® (vonoprazan)
$AstraZeneca(AZN.US$ : Imfinzi + chemotherapy - AdCom
$BeiGene(BGNE.US$ : TEVIMBRA (tislelizumab)
7
2
$AstraZeneca(AZN.US$ 🥳
📣 Imfinzi + chemotherapy gets approval for endometrial cancer
⇨ Imfinzi (durvalumab) + carboplatin & paclitaxel followed by Imfinzi mono in adult patients w/ primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR)
⇨ based on DUO-E Ph3 trial results 🧬
» showed reduced risk of disease progression or death by 58% 🆚 chemotherapy
📣 Imfinzi + chemotherapy gets approval for endometrial cancer
⇨ Imfinzi (durvalumab) + carboplatin & paclitaxel followed by Imfinzi mono in adult patients w/ primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR)
⇨ based on DUO-E Ph3 trial results 🧬
» showed reduced risk of disease progression or death by 58% 🆚 chemotherapy
6
The term 'GRANOLAS' was coined by Goldman Sachs in 2020 based on a loose acronym of the stocks' names. It includes GlaxoSmithKline, Roche, ASML, Nestlé, Novartis, Novo Nordisk, L'Oréal, LVMH, AstraZeneca, SAP and Sanofi.
2
$Esperion Therapeutics(ESPR.US$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
Read more